|
1
|
Siegel RL, Wagle NS, Cercek A, Smith RA
and Jemal A: Colorectal cancer statistics, 2023. CA Cancer J Clin.
73:233–254. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Azwar S, Seow HF, Abdullah M, Faisal Jabar
M and Mohtarrudin N: Recent updates on mechanisms of resistance to
5-fluorouracil and reversal strategies in colon cancer treatment.
Biology (Basel). 10:8542021.PubMed/NCBI
|
|
4
|
Ríos-Hoyo A, Monzonís X, Vidal J, Linares
J and Montagut C: Unveiling acquired resistance to anti-EGFR
therapies in colorectal cancer: A long and winding road. Front
Pharmacol. 15:13984192024. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Suetsugu T, Mori R, Futamura M, Fukada M,
Tanaka H, Yasufuku I, Sato Y, Iwata Y, Imai T, Imai H, et al:
Mechanism of acquired 5FU resistance and strategy for overcoming
5FU resistance focusing on 5FU metabolism in colon cancer cell
lines. Oncol Rep. 45:272021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wong RSY: Apoptosis in cancer: From
pathogenesis to treatment. J Exp Clin Cancer Res. 30:872011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Danial NN and Korsmeyer SJ: Cell death:
Critical control points. Cell. 116:205–219. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Youle RJ and Strasser A: The BCL-2 protein
family: Opposing activities that mediate cell death. Nat Rev Mol
Cell Biol. 9:47–59. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kirkin V, Joos S and Zörnig M: The role of
Bcl-2 family members in tumorigenesis. Biochim Biophys Acta.
1644:229–249. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Oltersdorf T, Elmore SW, Shoemaker AR,
Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges
J, Hajduk PJ, et al: An inhibitor of Bcl-2 family proteins induces
regression of solid tumours. Nature. 435:677–681. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pfeffer CM and Singh ATK: Apoptosis: A
target for anticancer therapy. Int J Mol Sci. 19:2018. View Article : Google Scholar
|
|
13
|
Diepstraten ST, Anderson MA, Czabotar PE,
Lessene G, Strasser A and Kelly GL: The manipulation of apoptosis
for cancer therapy using BH3-mimetic drugs. Nat Rev Cancer.
22:45–64. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lew TE and Seymour JF: Clinical
experiences with venetoclax and other pro-apoptotic agents in
lymphoid malignancies: Lessons from monotherapy and chemotherapy
combination. J Hematol Oncol. 15:752022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nita ME, Ono-Nita SK, Tsuno N, Tominaga O,
Takenoue T, Sunami E, Kitayama J, Nakamura Y and Nagawa H: Bcl-X(L)
antisense sensitizes human colon cancer cell line to
5-fluorouracil. Jpn J Cancer Res. 91:825–832. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lee WS, Park YL, Kim N, Oh HH, Son DJ, Kim
MY, Oak CY, Chung CY, Park HC, Kim JS, et al: Myeloid cell
leukemia-1 is associated with tumor progression by inhibiting
apoptosis and enhancing angiogenesis in colorectal cancer. Am J
Cancer Res. 5:101–113. 2015.PubMed/NCBI
|
|
17
|
Luo MJ, Palmieri M, Riffkin CD,
Sakthianandeswaren A, Djajawi TM, Hirokawa Y, Shuttleworth V, Segal
DH, White CA, Nhu D, et al: Defining the susceptibility of
colorectal cancers to BH3-mimetic compounds. Cell Death Dis.
11:7352020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang H, Xue J, Hessler P, Tahir SK, Chen
J, Jin S, Souers AJ, Leverson JD and Lam LT: Genomic analysis and
selective small molecule inhibition identifies BCL-X(L) as a
critical survival factor in a subset of colorectal cancer. Mol
Cancer. 14:1262015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Scherr AL, Mock A, Gdynia G, Schmitt N,
Heilig CE, Korell F, Rhadakrishnan P, Hoffmeister P, Metzeler KH,
Schulze-Osthoff K, et al: Identification of BCL-XL as highly active
survival factor and promising therapeutic target in colorectal
cancer. Cell Death Dis. 11:8752020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Greaves G, Milani M, Butterworth M, Carter
RJ, Byrne DP, Eyers PA, Luo X, Cohen GM and Varadarajan S: BH3-only
proteins are dispensable for apoptosis induced by pharmacological
inhibition of both MCL-1 and BCL-XL. Cell Death Differ.
26:1037–1047. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ishikawa K, Kawano Y, Arihara Y, Kubo T,
Takada K, Murase K, Miyanishi K, Kobune M and Kato J: BH3 profiling
discriminates the anti-apoptotic status of 5-fluorouracil-resistant
colon cancer cells. Oncol Rep. 42:2416–2425. 2019.PubMed/NCBI
|
|
22
|
Wang L, Doherty GA, Judd AS, Tao ZF,
Hansen TM, Frey RR, Song X, Bruncko M, Kunzer AR, Wang X, et al:
Discovery of A-1331852, a first-in-class, potent, and
orally-bioavailable BCL-XL inhibitor. ACS Med Chem Lett.
11:1829–1836. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Maeda A, Takahashi H, Harata S, Watanabe
K, Yanagita T, Suzuki T, Ushigome H, Nakai N, Maeda Y, Hirokawa T,
et al: The interaction between cancer-associated fibroblasts and
cancer cells enhances Bcl-xL and Mcl-1 in colorectal cancer.
Anticancer Res. 42:1277–1288. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Takahashi H, Chen MC, Pham H, Matsuo Y,
Ishiguro H, Reber HA, Takeyama H, Hines OJ and Eibl G: Simultaneous
knock-down of Bcl-xL and Mcl-1 induces apoptosis through Bax
activation in pancreatic cancer cells. Biochim Biophys Acta.
1833:2980–2987. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Maeda Y, Takahashi H, Nakai N, Yanagita T,
Ando N, Okubo T, Saito K, Shiga K, Hirokawa T, Hara M, et al:
Apigenin induces apoptosis by suppressing Bcl-xL and Mcl-1
simultaneously via signal transducer and activator of transcription
3 signaling in colon cancer. Int J Oncol. 52:1661–1673.
2018.PubMed/NCBI
|
|
26
|
Sitthisuk P, Innajak S, Poorahong W,
Samosorn S, Dolsophon K and Watanapokasin R: Effect of Acacia
concinna extract on apoptosis induction associated with
endoplasmic reticulum stress and modulated intracellular signaling
pathway in human colon HCT116 cancer cells. Nutrients. 16:37642024.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Murakami Y, Kazuno H, Emura T, Tsujimoto
H, Suzuki N and Fukushima M: Different mechanisms of acquired
resistance to fluorinated pyrimidines in human colorectal cancer
cells. Int J Oncol. 17:277–283. 2000.PubMed/NCBI
|
|
28
|
Leverson JD, Phillips DC, Mitten MJ,
Boghaert ER, Diaz D, Tahir SK, Belmont LD, Nimmer P, Xiao Y, Ma XM,
et al: Exploiting selective BCL-2 family inhibitors to dissect cell
survival dependencies and define improved strategies for cancer
therapy. Sci Transl Med. 7:279ra2402015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tirendi S, Marengo B, Domenicotti C, Bassi
AM, Almonti V and Vernazza S: Colorectal cancer and therapy
response: A focus on the main mechanisms involved. Front Oncol.
13:12081402023. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhu H, Guo W, Zhang L, Davis JJ, Teraishi
F, Wu S, Cao X, Daniel J, Smythe WR and Fang B: Bcl-XL small
interfering RNA suppresses the proliferation of
5-fluorouracil-resistant human colon cancer cells. Mol Cancer Ther.
4:451–456. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Maji S, Panda S, Samal SK, Shriwas O, Rath
R, Pellecchia M, Emdad L, Das SK, Fisher PB and Dash R: Bcl-2
antiapoptotic family proteins and chemoresistance in cancer. Adv
Cancer Res. 137:37–75. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ramesh P and Medema JP: BCL-2 family
deregulation in colorectal cancer: Potential for BH3 mimetics in
therapy. Apoptosis. 25:305–320. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Scherr AL, Gdynia G, Salou M,
Radhakrishnan P, Duglova K, Heller A, Keim S, Kautz N, Jassowicz A,
Elssner C, et al: Bcl-xL is an oncogenic driver in colorectal
cancer. Cell Death Dis. 7:e23422016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jin-Song Y, Zhao-Xia W, Cheng-Yu L,
Xiao-Di L, Ming S, Yuan-Yuan G and Wei D: Prognostic significance
of Bcl-xL gene expression in human colorectal cancer. Acta
Histochem. 113:810–814. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang Y, Ma L, Xu Y, Liu Y, Li W, Cai J and
Zhang Y: Enalapril overcomes chemoresistance and potentiates
antitumor efficacy of 5-FU in colorectal cancer by suppressing
proliferation, angiogenesis, and NF-κB/STAT3-regulated proteins.
Cell Death Dis. 11:4772020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Townsend PA, Kozhevnikova MV, Cexus ONF,
Zamyatnin AA Jr and Soond SM: BH3-mimetics: Recent developments in
cancer therapy. J Exp Clin Cancer Res. 40:3552021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang L, Ramesh P, Steinmetz M and Medema
JP: BH3 mimetic sensitivity of colorectal cancer cell lines in
correlation with molecular features identifies predictors of
response. Int J Mol Sci. 22:38112021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nwosu GO, Ross DM, Powell JA and Pitson
SM: Venetoclax therapy and emerging resistance mechanisms in acute
myeloid leukaemia. Cell Death Dis. 15:4132024. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Al-Zebeeby A, Vogler M, Milani M, Richards
C, Alotibi A, Greaves G, Dyer MJS, Cohen GM and Varadarajan S:
Targeting intermediary metabolism enhances the efficacy of BH3
mimetic therapy in hematologic malignancies. Haematologica.
104:1016–1025. 2019. View Article : Google Scholar : PubMed/NCBI
|
